You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
個股熱度排行 | 2月8日港股收盤

根據uSMART輿情監測數據,8日港股交易時段,市場關注指數最高的3只股票是藥明生物、藥明康德、阿裏健康。

2月8日—港股關注排行TOP3

輿情變化榜單

藥明生物

個股K線圖

關注度第一爲藥明生物,該股今日收盤下跌22.77%,報於62.25港元。近5個交易日累計下跌19.37%。在消息面和社交媒體方面,輿情以看空爲主。較被市場關注的消息有:

藥明康德澄清未被美國列入「未經證實名單」 無持有藥明生物股份

藥明生物初段瀉30%創近年半低 附屬遭美國商務部列入未覈實清單

藥明康德

個股K線圖

關注度第二爲藥明康德,該股今日收盤下跌11.36%,報於100.70港元。近5個交易日累計下跌7.27%。在消息面和社交媒體方面,輿情以看空爲主。較被市場關注的消息有:

A股三大指數集體低開滬指低開0.03% CRO板塊走低藥明康德跌停

發生了什麼?創業板指暴跌逾4%!“寧王”跌近9%,藥明康德閃崩跌停

阿裏健康

個股K線圖

關注度第三爲阿裏健康,該股今日收盤下跌7.52%,報於5.78港元。近5個交易日累計下跌3.51%。在消息面和社交媒體方面,輿情以看空爲主。較被市場關注的消息有:

恆生科技指數跌幅擴大至2% 萬國數據、阿裏健康跌近7%

科指午後跌幅曾擴至2.6% 阿裏巴巴、嗶哩嗶哩及阿裏健康跌逾3.5%-7%

此外,監測期內有1只股票的輿情出現大扭轉,意味着在消息面上出現了可能影響公司股價趨勢的事件或者轉折。

2月8日—港股輿情轉折預警

輿情變化榜單

藥明生物

個股K線圖

藥明生物輿情扭轉指數達97,目前輿情方向爲利空,表明公司出現了被投資者視作較大利空的消息。

其中較被市場關注的消息有:

藥明康德澄清未被美國列入「未經證實名單」 無持有藥明生物股份

藥明生物初段瀉30%創近年半低 附屬遭美國商務部列入未覈實清單

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account